Cardiome Pharma (CRME) to Cut Employee Headcount by 85%
Tweet Send to a Friend
Cardiome Pharma (Nasdaq: CRME) today announced that the Company is undertaking a significant workforce reduction as a response to the recently announced termination of Merck's development efforts relating to the vernakalant oral program.
The workforce reduction eliminates all positions focused on internal research activities along with certain supporting functions. The reduction in personnel will decrease the total number of employees by approximately 85%. The company expects to incur up to $5.0 million in severance and other charges related to this restructuring over the remainder of the year.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The workforce reduction eliminates all positions focused on internal research activities along with certain supporting functions. The reduction in personnel will decrease the total number of employees by approximately 85%. The company expects to incur up to $5.0 million in severance and other charges related to this restructuring over the remainder of the year.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Highway Holdings (HIHO) Surges, Halted on $400K Per Year Order
- Tessera (TSRA), Starboard Reach Agreement Over Board Composition
- AMD (AMD) Looks to Outdo Intel (INTC) in Battle of Performance Tablets with Latest SoC Offerings
Create E-mail Alert Related Categories
Corporate News, Trading HaltsRelated Entities
Layoffs
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
